Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer

Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer

Abstract Immune-related dissociated response (DR) has been recently recognized and have become a subject of ongoing interest. The purpose of the present study was to evaluate the frequency, treatment outcome, and predictors of DR in cancer patients with immune checkpoint inhibitors. We retrospective...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yaping Guan, Yu Cui, Yanhong Gong, Xiuju Liang, Xinyue Han, Yingcui Chen, Hong Xie, Yuekai Zhang, Baocheng Wang, Xin Ye, Jun Wang
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-12-01
Series:	Scientific Reports
Subjects:	Atypical response Pseudoprogression Dissociated response Programmed cell death protein-1 Immune checkpoint inhibitor Advanced cancer
Online Access:	https://doi.org/10.1038/s41598-024-84009-8
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
by: Patricia Martin‐Romano, et al.
Published: (2020-04-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024-07-01)

Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond
by: Jiaxin Wen, et al.
Published: (2025-04-01)

Phenomenology of dissociative symptoms: A comparison between individuals with dissociative disorders and high and low dissociative schizophrenia spectrum disorders
by: V.E. de Vries, et al.
Published: (2025-06-01)

Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report
by: Xiaodong Zhang, et al.
Published: (2025-06-01)

Temporal evolution of MRI findings and survival outcomes in patients with brain metastases after stereotactic radiosurgery
by: Ali Salbas, et al.
Published: (2025-05-01)

Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy—a retrospective study
by: Meiqin Zhu, et al.
Published: (2024-12-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Patient-specific HLA-I subtypes predict response to immune checkpoint blockade
by: Kyrillus S. Shohdy, et al.
Published: (2025-12-01)

Diagnostic difficulty in an adolescent with dissociative identity disorder
by: Kajal M. Patel, et al.
Published: (2025-02-01)

Prevalence of dissociative identity disorder among psychiatric outpatients in different cultural groups
by: May Mahmoud Abdellah, et al.
Published: (2025-07-01)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
by: Jingjing Duan, et al.
Published: (2018-09-01)

Dissociative Identity Disorder: A Comprehensive Review of Etiology, Diagnosis, Neurobiology, and Treatment
by: Monika Fidyk, et al.
Published: (2025-05-01)

Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors
by: Wangbin Ma, et al.
Published: (2025-12-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade
by: Victoria E. Stefan, et al.
Published: (2024-11-01)

Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
by: Jingqiu Li, et al.
Published: (2025-02-01)

Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade
by: Ting Zhang, et al.
Published: (2025-06-01)

Development of shellfish allergy after exposure to dual immune checkpoint blockade
by: Zachary J Brown, et al.
Published: (2018-01-01)

A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence
by: Xiang Liu, et al.
Published: (2024-11-01)

A single‐cell RNA labeling strategy for measuring stress response upon tissue dissociation
by: Anika Neuschulz, et al.
Published: (2022-12-01)

An item response theory analysis of the Dissociative Experiences Scale II: examining psychometric properties and longitudinal stability among Japanese adults
by: Tatsuya Ikeda, et al.
Published: (2025-01-01)

A system review of neoadjuvant immune checkpoint blockade for breast cancer
by: Yanle Ye, et al.
Published: (2025-03-01)

Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects
by: Can Lu, et al.
Published: (2025-06-01)

Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
by: Yanxiong Mao, et al.
Published: (2024-11-01)

Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
by: Mi Young Lim, et al.
Published: (2025-01-01)

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
by: Loulieta Nazerai, et al.
Published: (2023-12-01)

The association of immune-inflammation indices at multiple time points with treatment response and survival in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
by: Yaqing Li, et al.
Published: (2025-05-01)

Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
by: Madeline B. Torres, et al.
Published: (2025-04-01)

Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
by: Yuki Sasaki, et al.
Published: (2024-01-01)

Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
by: David Spillane, et al.
Published: (2025-04-01)

Application Research of Gas Hydrates Dissociation and Formation Technology
by: Yang Meng, et al.
Published: (2016-01-01)

The Effects of Mood Disorders and Dissociative Symptoms on Suicide Attempts
by: Halil ÖZCAN, et al.
Published: (2014-03-01)

Dissociation and Embodiment in Young Adult Literature: What Authors Need to Consider in the Climax
by: Alyssa Hollingsworth
Published: (2023-12-01)

Enhanced Prediction of Immune Checkpoint Blockade Response in Melanoma Using Ensemble Learning and a Hybrid Feature Selection Technique
by: Basant Badwy, et al.
Published: (2024-01-01)

The role of immunotherapy in the treatment of skin melanoma: a contemporary perspective
by: P. S. Masaeva
Published: (2024-06-01)

The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
by: Pedro C.A. Reis, et al.
Published: (2025-06-01)

Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)
by: Meichen Gu, et al.
Published: (2025-08-01)

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report
by: Carlotta Bertolina, et al.
Published: (2025-06-01)